Through competitively binding to AR, enzalutamide inhibits nuclear translocation of AR, androgen-mediated receptor activation, and the binding of AR to chromatin, resulting in inhibition of AR signaling and thereby leading to growth inhibition of prostate cancer cells, induction of apoptosis of prostate cancer cells and tumor regression in preclinical trials [13–15]. The gene discussed is AR; the disease is prostate cancer.